Sanofi (SNY) Competitors

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Which has preferable earnings & valuation, NVO or SNY?

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$42.12B	7.60	$14.64B	$3.38	21.22
Sanofi	$44.46B	2.77	$6.02B	$2.80	17.91

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	34.52%	80.94%	24.23%
Sanofi	14.56%	17.15%	9.80%

Which has more volatility and risk, NVO or SNY?

Novo Nordisk A/S has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Is NVO or SNY a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.3%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.2%. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Sanofi pays out 57.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Does the media refer more to NVO or SNY?

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Sanofi. MarketBeat recorded 43 mentions for Novo Nordisk A/S and 22 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 1.19 beat Sanofi's score of 0.98 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	33 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Sanofi	12 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate NVO or SNY?

Novo Nordisk A/S presently has a consensus price target of $112.00, indicating a potential upside of 56.18%. Sanofi has a consensus price target of $61.50, indicating a potential upside of 22.61%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11

Do insiders and institutionals hold more shares of NVO or SNY?

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.